1.68
Galmed Pharmaceuticals Ltd stock is traded at $1.68, with a volume of 13,170.
It is down -5.11% in the last 24 hours and down -33.33% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
See More
Previous Close:
$1.7704
Open:
$1.78
24h Volume:
13,170
Relative Volume:
0.43
Market Cap:
$2.78M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.5153
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
-12.04%
1M Performance:
-33.33%
6M Performance:
-59.12%
1Y Performance:
-61.06%
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLMD
Galmed Pharmaceuticals Ltd
|
1.68 | 2.78M | 0 | -6.91M | -6.14M | -3.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Feb-04-20 | Initiated | Craig Hallum | Buy |
Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-02-19 | Initiated | Canaccord Genuity | Buy |
Dec-12-18 | Initiated | B. Riley FBR | Buy |
Aug-02-18 | Reiterated | Maxim Group | Buy |
Jul-13-18 | Initiated | Stifel | Buy |
Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Initiated | ROTH Capital | Buy |
Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
Jul-31-17 | Reiterated | Maxim Group | Buy |
Aug-01-16 | Reiterated | Maxim Group | Buy |
Jul-06-16 | Resumed | ROTH Capital | Buy |
Mar-28-16 | Resumed | H.C. Wainwright | Buy |
Jun-23-15 | Initiated | H.C. Wainwright | Buy |
May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):